

MOL 63107

Role of phospholipase D2/phosphatidic acid signal transduction in μ - and δ -opioid receptor endocytosis

Li Q. Yang¹, Anja Seifert¹, Dai F.Wu, Xiaoqian Wang, Vladan Rankovic, Helmut Schröder, Lars O. Brandenburg, Volker Höllt, and Thomas Koch*

Institute of Pharmacology and Toxicology (L.Q.Y., A.S., D.F.W., V.R., H.S., V.H., T.K.) and the Institute of Molecular and Clinical Immunology (X.W.), Otto-von-Guericke University Magdeburg, Germany; and the Department of Anatomy and Cell Biology, University Hospital RWTH Aachen, Germany (L.O.B.)

MOL 63107

Running title:

Role of PLD2 signaling in opioid receptor endocytosis

Corresponding author:

Thomas Koch, Institute of Pharmacology and Toxicology, Otto-von-Guericke University, 39120 Magdeburg, Leipziger Str. 44, Germany.
Tel.: 49-391-671-5372; Fax: 49-391-671-5869;
E-mail: thomas.koch@med.ovgu.de

Number of text pages: 26

Number of tables: 0

Number of figures: 8

Number of references: 40

Number of words in the abstract: 248

Number of words in the introduction: 395

Number of words in the discussion: 1099

Abbreviations:

DOPr, δ -opioid receptor; MOPr, μ -opioid receptor; DPDPE, [D-Pen2, D-Pen5]enkephalin; DAMGO, [D-Ala2, Me Phe4, Glyol5]enkephalin; PLD, phospholipase D; PA, phosphatidic acid; PC, phosphatidylcholine; DAG, diacylglycerol; PAP, PA (or phosphatidate) Phosphohydrolase; DGK, DAG kinase; DOG, 1, 2-dioctanoyl-sn-glycerol; PKC, protein kinase C; MAPK, mitogen-activated protein kinase; EEA1, early endosome antigen 1; HA, influenza virus hemagglutinin-epitope; HEK293, human embryonic kidney 293; GPCR, G protein-coupled receptor; RIPA, Radioimmune precipitation assay; ABTS, 2,2'-azino-di-[3-ethylbenzthiazoline sulfonate (6)]; ANOVA, analysis of variance.

MOL 63107

Abstract

We recently demonstrated that opioid-induced activation of Phospholipase D2 (PLD2) enhances μ - and δ -opioid receptor (MOPr and DOPr) endocytosis/recycling and thus reduces the development of opioid receptor desensitization and tolerance. However, the mechanistic basis for the PLD2-mediated induction of opioid receptor endocytosis is currently unknown. Here we show that PLD2-generated phosphatidic acid (PA) might play a key role in facilitating the endocytosis of opioid receptors. However, PLD2-derived PA is known to be further converted to diacylglycerol (DAG) by PA phosphohydrolase (PPAP2). In fact, blocking of PA phosphohydrolase activity by propranolol or PPAP2-siRNA transfection, both significantly attenuated agonist-induced opioid receptor endocytosis. The primary importance of PA-derived DAG in the induction of opioid receptor endocytosis was further supported by the finding that increasing the DAG level by inhibiting the reconversion of DAG into PA with the DAG kinase inhibitor R59949 or the addition of the synthetic cell-permeable DAG analog DOG, further increased the agonist-induced opioid receptor endocytosis. Moreover, addition of DOG bypasses the PLD2-siRNA- or PPAP2-siRNA-mediated impairment of DAG synthesis and resulted in a restoration of agonist-induced opioid receptor internalization. Further studies established a functional link between PA-derived DAG and the activation of p38 MAPK and the subsequent phosphorylation of the Rab5 effector EEA1, which has been recently demonstrated to be required for the induction of MOPr endocytosis. Taken together, our results revealed that the regulation of opioid receptor endocytosis by PLD2 involves the conversion of its product PA to DAG resulting in an activation of the p38 MAPK pathway.

MOL 63107

Introduction

Opioids are classically associated with phenomena such as analgesia, respiratory depression, and addiction. Up to date three opioid receptor subtypes, mu, delta and kappa, have been identified, which belong to the G protein coupled receptor (GPCR) family. Agonist-induced internalization of opioid receptors via clathrin-dependent pathway is one important regulatory event of opioid receptor signal transduction. Recently, our group has found that Phospholipase D2 (PLD2) modulates agonist-induced MOPr endocytosis (Koch *et al.*, 2003). Phospholipase D (PLD) is an ubiquitous enzyme present in organisms ranging from bacteria, plants, animals to human. It hydrolyzes phosphatidylcholine (PC) to release choline and phosphatidic acid (PA), which is an important bioactive lipid. During recent years, two mammalian PLD subtypes, PLD1 and PLD2, have been cloned (Frohman *et al.*, 1999). Subcellular fractionation studies showed that PLD1 is present predominantly in intracellular membranes, e.g. endoplasmic reticulum, Golgi and vesicular compartments, whereas PLD2 is mainly distributed within the plasma membrane (Du *et al.*, 2004). PLD plays an important role in basic cell functions, such as signal transduction, cytoskeletal reorganization, and cellular proliferation (Ghosch *et al.*, 2003; Jenkins and Frohman, 2005; Zouwail *et al.*, 2005). In addition, PLD and its product PA have been also shown to be involved in endocytosis and vesicular trafficking of other receptors, such as angiotensin II receptor endocytosis (Du *et al.*, 2004) and epidermal growth factor endocytosis (Shen *et al.*, 2001). It is also known that PA is converted into diacylglycerol (DAG) by PA phosphohydrolase, however, little is known about the role of PA-derived DAG in the regulation of GPCR endocytosis.

Therefore, in the present study we investigated the role of PLD2-derived PA and DAG in the regulation of agonist-induced opioid receptor endocytosis. We first provide evidence that PLD2 activity is required for agonist-induced MOPr- and DOPr internalization and that its product PA plays a crucial role in this process. Then we found that the conversion of PA into DAG is a prerequisite for the PLD2-mediated enhancement of the agonist-induced MOPr and DOPr endocytosis and that this DAG-effect is PKC-independent. Further evidence demonstrates that the PLD2-PA-DAG pathway is involved in the opioid receptor-mediated activation of p38 mitogen-activated protein kinase (MAPK). Thus our results are in line with previous findings demonstrating an important role of p38 MAPK activation in the induction of endocytotic receptor

MOL 63107

trafficking (Cavalli *et al.*, 2001; Mace *et al.*, 2005; McLaughlin *et al.*, 2006; Vergaraiaurequi *et al.*, 2006).

Materials and Methods

Reagents. [D-Ala², N-Me-Phe⁴, Gly⁵-ol]-enkephalin (DAMGO) and [D-Pen², D-Pen⁵]enkephalin (DPDPE) were purchased from Bachem (Heidelberg, Germany). [³H]Naltrindol was obtained from NEN (Köln, Germany). 1-butanol was from Merck (Darmstadt, Germany) and Chelerythrine chloride was from Sigma (ST. Louis, MO). Other substances were purchased from Calbiochem (La Jolla, CA) unless otherwise indicated.

Epitope tagging and cloning of cDNA. A HA epitope tag sequence MYPYDVPDYA was added to the N-terminus of the mu- and delta-opioid receptor cDNA using polymerase chain reaction (PCR) and then subcloned into pEAK10 expression vector containing the puromycin resistance gene (Edge Biosystems, Gaithersburg, MD, USA), which generated the plasmids pEAK10-HAMOPr and pEAK10-HADOPr.

Generation of stable cell lines expressing mu- or delta-opioid receptor. To generate MOPr- or DOPr-receptor expressing cell line, HEK293 cells were transfected with the pEAK10-HAMOPr or pEAK10-HADOPr plasmid by the calcium phosphate precipitation method and selected with 1.25 µg/ml puromycin (Sigma, Deisenhofen, Germany) as previously described (Koch *et al.*, 2004; Koch *et al.*, 2003; Koch *et al.*, 2006). Stable transfectants were selected with 1.25 µg/ml puromycin and 500 µg/ml G418 (Life Technologies, Eggenstein, Germany) in Dulbecco's modified Eagle's medium (DMEM) (Cambrex, Verviers, Belgium) containing 10 % fetal calf serum. Multi-clones were used for the further studies. Receptor expression of the stable transfectants were monitored and selected by radioligand binding assay and confocal microscopy as previously described (Koch *et al.*, 2004; Koch *et al.*, 2003; Koch *et al.*, 2006).

Transient siRNA transfection method. HEK293 or SHSY-5Y cells (5×10^4 cells) were seeded in 6 well dishes and incubated over night. Lipofectamine 2000 was used for siRNA-transfection according to the manufacturer's instructions. For downregulation of PLD2-expression the cells were transfected with 150 ng PLD2-siRNA (5-

MOL 63107

GAUGCAGGCAACAGAGAGATT-3) and 1.5 μ g of PLD2-siRNA containing pGFR-PLD2 vector (Kim *et al.*, 2005). For downregulation of PPAP2A and PPAP2B expression the cells were transfected with 150 ng PPAP2A-siRNA (5-AGGAAUAAUACAUAAGCCATT-3) and 150 ng PPAP2B-siRNA (5-ACUGAAAACUGGUGAGACATT-3). Six hours after transfection medium was changed and cells were incubated for additional 36 hours. Then cells were treated as indicated and prepared for Western blot analyses or analyses of receptor internalization.

RNA preparation and real time RT-PCR. Isolation of total cellular RNA, synthesis of cDNA, and real-time PCR analysis was performed as previously described (Seifert *et al.*, 2008). For RT-PCR reactions two microliters cDNA were used and quantitative RT-PCR was performed in a total volume of 20 μ l on a LightCycler instrument using the LightCycler–Fast Start DNA Master SYBR Green I kit (both from Roche). Conditions were as follows: PPAP2A-primers: forward 5'-GGGAATCACTATCCGAGCAA-3' and reverse 5'-TGTGCATCCAAGAGGCATAG-3' (preincubation, 8 min at 95°C, 50 cycles, 5 s at 95°C, 10 s at 60°C, and 6 s at 72°C); PPAP2B-primers: forward 5'-CGACTTCGGTTACTGCCTTC-3' and reverse 5'-GCTTCTCTGGCTCCTTCTGA-3' (preincubation, 8 min at 95°C, 50 cycles, 5 s at 95°C, 10 s at 60°C, and 6 s at 72°C); ribosomal 18S (Seifert *et al.*, 2008) (preincubation, 8 min at 95°C, 50 cycles, 5 s at 95°C, 6 s at 60°C, and 6 s at 72°C). Melting curves were generated for verification of the PCR-product. Additionally, gel electrophoresis was performed to proof the quality of the PCR product. C_t values for all genes analysed were determined three times, averaged, and normalized to values for the endogenous control 18S. The relative mRNA amounts were calculated by using the $\Delta\Delta C_t$ method (Seifert *et al.*, 2008).

MOL 63107

Radioligand binding assay. The binding characteristics of the MOPr and DOPr were determined by saturation binding assays on membranes prepared from stably transfected cells. Dissociation constant (K_D) and number of [^3H]DAMGO or [^3H]naltrindol binding sites (B_{max}) were calculated by Scatchard analysis using at least seven concentrations of radioligand in a range from 0.025 nM to 25 nM. Nonspecific binding was determined as radioactivity bound in the presence of 1 μM unlabeled DAMGO or Naltrindol. By the ratio of specific bound radioligand per mg protein, the number of [^3H]DAMGO or [^3H]naltrindol binding sites in membrane binding assay reflects the amount of total MOPr or DOPr, respectively.

Quantitative analysis of receptor internalization. Cells were seeded at a density of 2×10^5 per well and grown overnight in poly-L-lysine-coated 24-well plates. They were treated as indicated with or without agonist in Ultra MEM at 37°C for 30 min. Then, cells were incubated with rabbit anti-HA antibody (1 $\mu\text{g}/\text{ml}$) in Ultra MEM at 4°C for 1.5 h to label HA-tagged surface receptors. Subsequently, cells were fixed with 4 % paraformaldehyde for 40 min and incubated with peroxidase-conjugated anti-rabbit antibody (1:1000, Amersham Biosciences) for 2 h at room temperature. Colour was developed with 250 μl of ABTS solution (Roche Molecular Biochemicals). After 10–20 min of rotation, 200 μl of the substrate solution from each well were transferred to a 96-well plate and measured at 405 nm with a microtiter plate reader. Agonist-induced receptor internalization was calculated as the percentage loss of surface opioid receptors compared to control cells without agonist treatment.

Preparation of cell lysates and Western blotting analysis. Cells were seeded in 12-well plate at a density of 1.8×10^5 per well. After 24 hours, cells were further serum-starved for 16 h in DMEM containing 1 % fetal calf serum. After treatment as indicated, cells were washed with ice-cold PBS and lysed on ice with RIPA buffer containing fresh-prepared proteinase inhibitors and phosphatase inhibitors for 1 hour. Cell lysate was centrifuged at 14,000 rpm for 20 min and the total protein in supernatant was quantified. Supernatants containing same amount of total proteins were subjected to 10 % SDS-polyacrylamide gel electrophoresis. After electroblotting, the nitrocellulose membrane was blocked with 3 % non-fat milk for 30 min, and incubated with 1 $\mu\text{g}/\text{ml}$ polyclonal rabbit anti-human PLD2 antibody (Sigma Aldrich), 1 $\mu\text{g}/\text{ml}$ phospho-p38 MAPK (Thr180/Tyr182) rabbit antibody (Cell signaling), 5 $\mu\text{g}/\text{ml}$ phospho-Thr mouse antibody

MOL 63107

(Sigma) or 1 $\mu\text{g/ml}$ EEA1 goat antibody (Santa Cruz) overnight at 4°C. Binding of primary antibody was detected with secondary anti-rabbit antibody or anti-mouse antibody for 1 h at room temperature, followed by detection using enhanced chemiluminescence (ECL) detection system. To detect other protein or beta-actin, the same membrane was treated with 1 % sodium azide in TBS for 45 min and then subjected to standard immunoblotting procedure as previously described (Koch et al., 2004; Koch et al., 2003).

Results

Agonist-induced opioid receptor endocytosis requires PLD2-mediated PA synthesis.

By using a dominant negative PLD2 mutant we have previously shown that PLD2 activity is required for agonist-induced MOPr and DOPr endocytosis (Koch *et al.*, 2003; Koch *et al.*, 2006). To confirm these findings, in the present study we reduced the endogenous PLD2 expression level by transfecting MOPr and DOPr expressing HEK293 cells with PLD2-siRNA and determined the effect on the agonist-induced opioid receptor endocytosis (Fig. 1A, C and Fig. 2A, C). The stable expression of MOPr or DOPr in HEK293 cells was monitored by ligand binding experiments. These saturation binding experiments revealed no substantial differences between MOPr and DOPr expressing cells with respect to their numbers of binding sites (B_{max} ; 1329 \pm 399 and 1247 \pm 352 fmol/mg protein for MOPr and DOPr, respectively). The affinities (K_D) of the MOPr for [^3H]DAMGO and DOPr for [^3H]naltrindol were 1.4 \pm 0.3 and 0.142 \pm 0.048 nM, respectively. In Fig. 1C and 2C it is demonstrated that blocking PLD2 activity by cotransfection of PLD2-siRNA completely blocked the agonist-induced MOPr- and DOPr-endocytosis, which is in line with our previous findings (Koch *et al.*, 2003; Koch *et al.*, 2006). It is further known that PLD2 catalytic activity results in the production of PA by hydrolyzing phosphatidylcholine. Therefore, we next investigated the effect of blocking PLD2-mediated PA production for the induction of opioid receptor endocytosis. For inhibition of PA production the primary alcohol 1-butanol was used, which is known to be preferentially used over water by PLD2 in the transphosphatidyl reaction to generate phosphatidylalcohol instead of phosphatidic acid. Quantitative internalization analysis shows that in the presence of 1-butanol, the agonist-induced MOPr and DOPr endocytosis was strongly reduced (Fig. 1C and 2C). To ensure that the 1-butanol effect was not simply an alcohol artifact, in control experiments the

MOL 63107

secondary alcohol isobutanol was used which showed no effect on the agonist-induced opioid receptor internalization (data not shown). These results strongly suggest that PLD2-mediated PA production is required for agonist-induced opioid receptor endocytosis.

The conversion of PLD2-derived PA into DAG is involved in agonist-induced MOPr and DOPr endocytosis in a PKC-independent way. PLD2 hydrolyzes PC to form PA, which can be further dephosphorylated to diacylglycerol (DAG) by PA phosphohydrolase (PAP) (Sciorra and Morris, 2002). DAG in turn can be regenerated to PA by DAG kinase (DGK) (Jenkins and Frohman, 2005). Therefore, here we investigated the role of PA-derived DAG for opioid receptor endocytosis.

First the conversion from PA to DAG was inhibited by using propranolol, an effective phosphatidic acid phosphatase (PAP) blocker that has been used in numerous studies (Albert *et al.*, 2005; Grkovich *et al.*, 2006). As seen in Fig. 1C and 2C, when the conversion from PA to DAG was inhibited by propranolol, agonist-induced MOPr and DOPr endocytosis was drastically decreased.

However, to exclude potential unspecific effects of the PAP blocker propranolol we next used siRNA technology to confirm the essential role of PA-derived DAG in the induction of MOPr- and DOPr-internalization. Thus, in MOPr and DOPr expressing cells we cotransfected PPAP2A/B-siRNA to downregulate the expression of phosphatidic acid phosphatase 2 which mediates the conversion of PA into DAG (Fig. 1B and 2B). As shown in Figure 1C and 2C, transfection of PPAP2A/B-siRNA led to a complete inhibition of the agonist-induced MOPr- and DOPr-internalization. Together, these data revealed that the conversion from PLD2-derived PA to DAG is important for the PLD2-mediated induction of opioid receptor endocytosis.

To further verify the stimulatory effect of DAG on opioid receptor endocytosis, we increased the PA-derived DAG accumulation by inhibiting the reconversion of DAG to PA with the most commonly used DGK inhibitor R59949. R59949 specifically acts on the catalytic domain of DGK and inhibits its catalytic activity (Jiang *et al.*, 2000). As shown in Fig. 1C and C, the inhibition of the conversion from DAG to PA augmented the DAMGO-induced MOPr endocytosis and DPDPE-induced DOPr endocytosis significantly.

In order to obtain direct evidence that agonist-induced opioid receptor endocytosis is facilitated by DAG, we incubated the MOPr or DOPr expressing cells with the cell-permeable DAG analog 1,2-dioctanoyl-sn-glycerol (DOG) (Lucas *et al.*, 2003). In fact, compared to the

MOL 63107

treatment with DAMGO or DPDPE alone, the presence of DOG increased the agonist-induced MOPr and DOPr endocytosis (Fig. 3A and B). Moreover, DOG application overcomes the inhibition of agonist-induced opioid receptor endocytosis by PLD2-siRNA or PPAP2-siRNA transfection (Fig. 3A and B), indicating the key role of DAG in the induction of opioid receptor endocytosis.

Since DAG is known to activate protein kinase C (PKC), we next investigated whether the activation of PKC is involved in DAG-mediated opioid receptor endocytosis. Therefore, we used two specific PKC inhibitors, chelerythrine chloride and calphostin C to block DAG-mediated PKC activation. The inhibition of PKC by either chelerythrine chloride or calphostin C did not impair DOG-induced MOPr and DOPr endocytosis (Fig. 3A and B), ruling out that PKC is involved in the DAG-effect on MOPr and DOPr endocytosis.

The function of PLD2 in opioid receptor endocytosis involves activation of p38 MAP Kinase. Recently p38 MAPK has been identified to regulate the endocytic trafficking of various receptors, such as AMPA receptor, MOPr, platelet-activating factor receptor and epidermal growth factor receptor (Cavalli *et al.*, 2001; Mace *et al.*, 2005; McLaughlin *et al.*, 2006; Vergaraiaurequi *et al.*, 2006). For the MOPr it has been shown that the receptor-internalizing μ -agonist DAMGO can rapidly stimulate p38 MAPK activation and that this activation is a prerequisite for the subsequent MOPr endocytosis (Mace *et al.*, 2005). In contrast, the non-internalizing μ -agonist morphine was shown not to activate p38 MAPK (Mace *et al.*, 2005). However, the mechanisms through which opioid receptors mediate the activation of p38 MAPK are still unknown. We have previously shown, that receptor-internalizing μ -agonists, like DAMGO, activate PLD2, whereas non-internalizing agonists, such as morphine, can not and that this agonist-selective PLD2 activation is essential for opioid receptor endocytosis. To investigate whether the opioid-mediated PLD2 activation is involved in the activation of p38 MAPK we first tested the effect of blocking PLD2-derived PA synthesis on the opioid-induced p38 MAPK activation.

Using a specific antibody against phosphorylated p38 MAPK (Thr180/Tyr182), we first tested the activation of p38 MAPK by the agonist DAMGO in MOPr expressing cells as well as by DPDPE in DOPr expressing cells (Fig. 4A). The increase of p38 MAPK phosphorylation was readily detected after 5 min of stimulation with DPDPE in DOPr-expressing cells or with DAMGO in MOPr expressing cells. For inhibition of PLD-derived PA synthesis we used the

MOL 63107

primary alcohol 1-butanol, which is known to be preferentially used over water by PLD in the transphosphatidylolation reaction forming phosphatidylalcohols at the expense of PA. This reaction is highly specific for primary alcohols, whereas secondary alcohols (such as isobutanol) are not utilized by PLD. After blocking PLD-derived PA synthesis by 1-butanol, the opioid-induced p38 MAPK phosphorylation was blocked and this effect was not simply due to a nonspecific alcohol effect, because the secondary alcohol isobutanol did not block the opioid-induced p38 MAPK activation. These results indicate that PLD activity and PA production are essential for p38 MAPK activation by both μ - and δ -opioid receptors (Fig. 4A).

But is the opioid-mediated activation of p38 MAPK via PLD2 really involved in the induction of opioid receptor endocytosis? To test this, we blocked p38 MAPK activation with the specific p38 MAPK inhibitor SB203580. We found that the agonist-induced endocytosis was attenuated by the pretreatment with the p38 MAPK inhibitor SB203580 for both MOPr and DOPr (Fig. 4B) which is consistent with the observations from Mace et al. (2005).

Our data revealed that inhibition of PLD2-activity by primary alcohol or PLD2-siRNA transfection blocks opioid-induced p38 MAPK activation for both MOPr and DOPr (Fig. 4A, Fig. 5B and Fig. 6B). Since PLD2 activation results in an increase of PA and subsequent in PA-derived DAG, it is possible that also the conversion of PA into DAG is involved in opioid receptor-mediated p38 MAPK activation. To address this issue, we inhibited the dephosphorylation of PA to DAG with the PAP inhibitor propranolol or PPAP2-siRNA transfection. The opioid-induced p38 MAPK phosphorylation in MOPr or DOPr expressing cells was remarkably impaired by propranolol (Fig. 5A and 6A) or PPAP2-siRNA (Fig. 5B and 6B), indicating an important role of the PA-derived DAG in the opioid receptor-mediated p38 MAPK activation.

In addition, we analyzed the effect of the DAG analog DOG on p38 MAPK activation. As shown in Fig. 5A and 6A, in MOPr or DOPr expressing cells, treatment with DOG alone was sufficient to induce p38 MAPK phosphorylation, which could not be blocked by the inhibition of PKC with chelerythrine chloride. When the cells were stimulated with the DOPr agonist DPDPE or the MOPr agonist DAMGO, respectively, the presence of DOG augmented the agonist-induced phosphorylation of p38 MAPK. Inhibition of PKC with chelerythrine chloride could not impair this augmented phosphorylation of p38 MAPK. Taken together, these data indicate that PA-derived DAG can activate p38 MAPK in a PKC-independent manner. Furthermore, the inhibition of p38 MAPK activation by PLD2-siRNA or PPAP2-siRNA could be bypassed by

MOL 63107

treatment with DOG, indicating the important role of DAG in the opioid-mediated activation of p38 MAPK (Fig. 5C and 6C).

Opioid-induced activation of p38 MAPK in neuronal cells is PLD2-mediated. To ensure that the requirement of PLD2 activity for the opioid-induced p38 MAPK activation was not an artifact of the HEK293 cell model, we examined whether this regulation also occurred in neuronal SHSY-5Y cells endogenously expressing MOPr and DOPr. Therefore, the SHSY-5Y cells were transfected or not transfected with nonsense-siRNA, PLD2-siRNA or PPAP2-siRNA and the effect of the μ -agonist DAMGO and δ -agonist DPDPE on the p38 MAPK activation was determined by western blot analyses. Our data revealed that inhibition of endogenous PLD2 activity by PLD2-siRNA transfection or inhibition of the PPAP2-mediated conversion of PLD2-derived PA into DAG by PPAP2-siRNA resulted in an inhibition of the DAMGO- and DPDPE-induced p38 MAPK activation (Fig. 7). These results emphasize the important physiological role of PLD2 activity and signal transduction in the opioid-mediated activation of p38 MAPK.

Opioid-induced EEA1 activation in neuronal cells requires PLD2 activity. Previous studies demonstrated, that p38 MAPK regulates MOPr endocytosis by phosphorylating the Rab5 effector EEA1 to regulate its recruitment to the plasma membrane (Mace *et al.*, 2005). To test whether this opioid-induced and p38 MAPK-mediated phosphorylation of EEA1 requires PLD2 activity, we examined the effect of PLD2- and PPAP2-inhibition on the opioid-induced phosphorylation of endogenous EEA1 in neuronal SHSY-5Y cells. Therefore, the SHSY-5Y cells were transfected or not transfected with nonsense-siRNA, PLD2-siRNA or PPAP2-siRNA and the effect of the μ -agonist DAMGO and δ -agonist DPDPE on the EEA1 phosphorylation was determined by western blot analyses. Our data revealed that inhibition of endogenous PLD2 activity by PLD2-siRNA transfection or inhibition of the PPAP2-mediated conversion of PLD2-derived PA into DAG by PPAP2-siRNA resulted in an inhibition of the DAMGO- and DPDPE-induced EEA1 phosphorylation (Fig. 8). These results emphasize the important physiological role of PLD2 activity and signal transduction in the opioid-mediated activation of the Rab5 effector EEA1. Together with the previous findings, these results also clearly demonstrate that the conversion of PLD2-derived PA into DAG is directly linked with EEA1/Rab5 function in the regulation of MOPr endocytosis.

MOL 63107

Discussion

PLD hydrolyzes phosphatidylcholine to generate choline and PA, a bioactive lipid which has various functions in signal transduction, membrane trafficking, transformation and cytoskeletal dynamics. PLD activity has been shown to be regulated by a number of GPCRs including VPAC 1 and 2 and PAC1 receptor (McCulloch *et al.*, 2001), metabotropic glutamate receptors (Bhattacharya *et al.*, 2004; Kanumilli *et al.*, 2002; Shinomura *et al.*, 2000), m1-m4 muscarinic receptors (Mitchell *et al.*, 2003; Sandmann *et al.*, 1991), the endothelin receptor (Ambar and Sokolovsky, 1993), the α 2-adrenergic receptor (MacNulty *et al.*, 1992), the D2 dopamine receptor (Senogles, 2000), the somatostatin sstr2 receptor (Grodnitzky *et al.*, 2007), the 5HT2A-receptor (Robertson *et al.*, 2003), and the cannabinoid receptor isoform 1 (Koch *et al.*, 2006). We have recently demonstrated that PLD2 is also activated by the μ - and δ -opioid receptors and that this PLD2 activation is ARF6-dependent and essential for the agonist-induced opioid receptor endocytosis (Koch *et al.*, 2003; Koch *et al.*, 2006; Rankovic *et al.*, 2009). Our results also revealed that a direct interaction between the PLD2 and opioid receptor is required for a sufficient opioid-induced PLD2 activation (Koch *et al.*, 2003; Koch *et al.*, 2006). Our results are consistent with other findings demonstrating that PLD activity is involved in the endocytosis of various receptors such as the angiotensin II receptor (Du *et al.*, 2004), B-cell antigen receptor (Snyder and Pierce, 2006), class 1 metabotropic glutamate receptors (Bhattacharya *et al.*, 2004), and epidermal growth factor (EGF) receptor (Lee *et al.*, 2006). However, the mechanistic basis for the PLD2-mediated regulation of receptor endocytosis is only barely understood. It is suggested that the PLD2-derived PA plays a key role in the induction of receptor endocytosis via activation of type I phosphoinositide-4-phosphate 5-kinases, which results in an increased phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P₂] level of the membrane (Jones *et al.*, 2000). Clathrin, dynamin and proteins of the AP-2 adapter complex contain domains that mediate their binding to PtdIns(4,5)P₂-harbouring membranes [reviewed in (Mousavi *et al.*, 2004)]. In addition, an increase in the level of PA after PLD2 activation results in a change of the physical properties, e.g. charge and pH, of cellular membranes, thereby facilitating vesicle formation.

MOL 63107

However, an alternative explanation arises from the data presented in this publication. We found that agonist-induced opioid receptor endocytosis involves PLD2-mediated p38 MAPK activation. This is in line with previous publications demonstrating that p38 MAPK is a regulator of receptor endocytic trafficking (Cavalli *et al.*, 2001; Mace *et al.*, 2005; McLaughlin *et al.*, 2006; Vergaraiaurequi *et al.*, 2006). The function of p38 MAPK in receptor endocytosis seems to be tightly related to the small GTPase Rab5, one of the key regulators of clathrin-dependent endocytosis. Rab5 coordinates multiple processes, such as the formation of clathrin-coated vesicles, their fusion with early endosomes and homotypic early endosome fusion, as well as motility of endosomes (Seachrist and Ferguson, 2003). It has been found that p38 MAPK regulates MOPr endocytosis by phosphorylating the Rab5 effectors EEA1 and Rabenosyn-5 to regulate their recruitment to the plasma membrane (Mace *et al.*, 2005). This is in line with the findings from the present study showing that blocking p38 MAPK activity results in a complete block of agonist-induced opioid receptor endocytosis.

Therefore, opioid-induced activation of p38 MAPK seems to be required for the opioid receptor endocytosis. Furthermore, several lines of evidence suggest that opioid-induced p38 MAPK activation requires PLD2 activity. First, inhibition of PLD2 expression by PLD2-siRNA completely blocks not only opioid receptor endocytosis but also opioid-induced p38 MAPK activation. Second, opioids that cannot induce receptor endocytosis, such as morphine, failed to activate both PLD2 and p38 MAPK (Koch *et al.*, 2003; Mace *et al.*, 2005). Third, inhibition of the PLD2-mediated PA synthesis by primary alcohols completely blocks not only opioid receptor endocytosis but also p38 MAPK activation. These observations are supported by other publications demonstrating a crucial role of PLD in the p38 MAPK activation pathways (Azuma *et al.*, 2007; Grab *et al.*, 2004). However, the mechanism how PLD activates p38 MAPK still needs to be elucidated.

Our findings indicate the PLD2-generated PA might play a key role in the activation of p38 MAPK and subsequent opioid receptor endocytosis. As mentioned above, PLD2-generated PA can be further converted into DAG by the family of enzymes known as phosphatidic acid phosphohydrolases (PAPs), which are highly active under physiological conditions (Sciorra and Morris, 2002). Furthermore, the PA-derived DAG can be reconverted to PA via phosphorylation by diacylglycerol kinases (DGKs). Thus, the regulation of PA and DAG levels appears to be tightly controlled via the activities of PAP and DGK. In fact, we found that agonist-induced MOPr and DOPr endocytosis as well as the p38 MAPK activation were remarkably reduced

MOL 63107

when the PAP activity was inhibited. Conversely, DGK inhibition significantly augmented both agonist-induced MOPr and DOPr endocytosis. These experiments indicate that the PA-derived DAG is involved in the endocytosis of opioid receptors and in the opioid-mediated p38 MAPK activation. This finding was further supported by the addition of the cell-permeable DAG analog, DOG. The presence of DOG strongly enhanced both agonist-induced MOPr and DOPr endocytosis as well as the p38 MAPK activation. Our finding that the DOG-treatment overcomes the inhibitory effect of PLD2-siRNA or PPAP2-siRNA transfection on the agonist-induced opioid receptor endocytosis and p38 MAPK activation indicated that DAG might have a key function upstream of p38 MAPK activation. Since DAG is a lipid second messenger which is known to activate lipid-dependent kinases such as classical and novel PKC families it was reasonable to suggest that this DAG-effect on the opioid receptor endocytosis and p38 MAPK activation is PKC-mediated. However, our data revealed that this is not the case. In fact, the observed effects of PA-derived DAG on receptor endocytosis and p38 MAPK activation seemed to be PKC-independent, because they could not be blocked by PKC inhibitors such as calphostin C or chelerythrine.

In addition to the findings with HEK293 cell model, we and others clearly demonstrate the physiological importance of PLD2- and p38 MAPK-activation for the opioid receptor endocytosis also in neuronal cells under more physiological conditions (Mace *et al.*, 2005; Rankovic *et al.*, 2009). This is further supported by our present results indicating that the opioid-induced p38 MAPK activation is PLD2-mediated also in neuronal SHSY-5Y cells, which endogenously express the MOPr and DOPr. We also provide evidence, that PLD2-derived PA and DAG synthesis is required for the opioid-induced p38 MAPK-mediated activation of the Rab5 effector EEA1 in neuronal SHSY-5Y cells, emphasizing the important role of EEA1/Rab5 activation in the opioid-mediated endocytosis. In summary, our results reveal that the metabolism from PLD2-generated PA to DAG influences agonist-induced opioid receptor endocytosis via activation of p38 MAPK.

Acknowledgements:

We thank Evelyn Kahl, Dana Meyer, and Karina Schäfer for excellent technical assistance.

MOL 63107

Reference:

Albert AP, Piper AS, and Large WA (2005) Role of phospholipase D and diacylglycerol in activating TRPC-like cation channels in rabbit ear artery myocytes. *J Physiol* **566**: 769-780.

Ambar I and Sokolovsky M (1993) Endothelin receptors stimulate both phospholipase C and phospholipase D activities in different cell lines. *Eur J Pharmacol* **245**: 31-41.

Azuma Y, Kosaka K, and Kashimata M (2007) Phospholipase D-dependent and -independent p38MAPK activation pathways are required for superoxide production and chemotactic induction, respectively, in the rat neutrophils stimulated by fMLP. *Eur J Pharmacol* **568**: 260-268.

Bhattacharya M, Babwah AV, Godin C, Anborgh PH, Dale LB, Poulter MO, and Ferguson SS (2004) Ral and phospholipase D2-dependent pathway for constitutive metabotropic glutamate receptor endocytosis. *J Neurosci* **24**: 8752-8761.

Cavalli V, Vilbois F, Corti M, Marcote MJ, Tamura K, Karin M, Arkinstall S, and Gruenberg J (2001) The stress-induced MAP kinase p38 regulates endocytotic trafficking via the GDI:Rab5 complex. *Mol Cell* **7**: 421-432.

Du G, Huang P, Liang BT, and Frohman MA (2004) Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. *Mol Biol Cell* **15**: 1024-1030.

Frohman MA, Sung TC, and Morris AJ (1999) Mammalian phospholipase D structure and regulation. *Biochim Biophys Acta* **1439**: 175-186.

Ghosch S, Moore S, Bell RM, and Dush M (2003) Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidic binding domain lead to tail and trunk abnormalities in developing zebrafish embryos. *J Biol Chem* **278**: 45690-45696.

MOL 63107

Grab LT, Kearns MW, Morris AJ and Daniel LW (2004) Differential role for phospholipase D1 and D2 in 12-O-tetradecanoyl-13-phorbol acetate-stimulated MAPK activation, Cox-2 and IL-8 expression. *Biochim Biophys Acta* **1636**: 29-39.

Grkovich A, Johnson CA, Buczynski MW, and Dennis EA (2006) Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. *J Biol Chem* **281**: 32978-32987.

Grodnitzky JA, Syed N, Kimber MJ, Day TA, Donaldson JG, and Hsu WH (2007) Somatostatin receptors signal through EFA6A-ARF6 to activate phospholipase D in clonal beta-cells. *J Biol Chem* **282**: 13410-13418.

Jenkins GM and Frohman MA (2005) Phospholipase D: a lipid centric review. *Cell Mol Life Sci*. **62**: 2305-2316.

Jiang Y, Sakane F, Kanoh H, and Walsh JP (2000) Selectivity of the diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidiny)ethyl]-2, 3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase subtypes. *Biochem Pharmacol* **59**: 763-772.

Jones DR, Sanjuan, MA, and Mérida I (2000) Type I alpha phosphatidylinositol 4-phosphate 5-kinase is a putative target for increased intracellular phosphatidic acid. *FEBS Lett* **476**: 160-165.

Kanumilli S, Toms NJ, Venkateswarlu K, Mellor H, and Roberts PJ (2002) Functional coupling of rat metabotropic glutamate 1a receptors to phospholipase D in CHO cells: involvement of extracellular Ca²⁺, protein kinase C, tyrosine kinase and Rho-A. *Neuropharmacology* **42**: 1-8.

Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, and Rossi JJ (2005) Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. *Nat Biotechnol* **23**: 222-226.

MOL 63107

Koch T, Brandenburg LO, Liang Y, Schulz S, Beyer A, Schröder H, and Höllt V (2004) Phospholipase D2 modulates agonist-induced μ -opioid receptor desensitization and resensitization. *J. Neurochem* **88**: 680-688.

Koch T, Brandenburg LO, Schulz S, Liang Y, Klein J, and Höllt V (2003) ADP-ribosylation factor-dependent Phospholipase D2 activation is required for agonist-induced μ -opioid receptor endocytosis. *J. Biol. Chem* **278**: 9979-9985.

Koch T, Schulz S, Pfeiffer M, Klutzny M, Schröder H, Kahl E, and Höllt V (2001) C-terminal splice variants of the mouse μ -opioid receptor differ in morphine-induced internalization and receptor resensitization. *J Biol Chem* **276**: 31408-31414.

Koch T, Wu DF, Yang LQ, Brandenburg LO, and Höllt V (2006) Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. *J Neurochem* **97**: 365-372.

Lee CS, Kim IS, Park JB, Lee MN, Lee HY, Suh PG, and Ryu SH (2006) The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis. *Nat Cell Biol* **8**: 477-484.

Lucas P, Ukhanov K, Leinders-Zufall T, and Zufall F (2003) A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC mutant mice: mechanism of pheromone transduction. *Neuron* **40**: 551-561.

Mace G, Miaczynska M, Zerial M, and Nebreda AR (2005) Phosphorylation of EEA1 by p38 MAP kinase regulates μ opioid receptor endocytosis. *EMBO J* **24**: 3235-3246.

MacNulty EE, McClue SJ, Carr IC, Jess T, Wakelam MJ, and Milligan G (1992) Alpha 2-C10 adrenergic receptors expressed in rat 1 fibroblasts can regulate both adenylyl cyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins. *J Biol Chem* **267**: 2149-2156.

MOL 63107

McCulloch DA, Lutz EM, Johnson MS, Robertson DN, MacKenzie CJ, Holland PJ, and Mitchell R (2001) ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. *Mol Pharmacol* **59**: 1523-1532.

McLaughlin NJ, Banerjee A, Kelher MR, Gamboni-Robertson F, Hamiel C, Sheppard FR, Moore EE, and Silliman CC (2006) Platelet-activating factor-induced clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation. *J Immunol* **176**: 7039-7050.

Mitchell R, Robertson DN, Holland PJ, Collins D, Lutz EM, and Johnson MS (2003) ADP-ribosylation factor-dependent phospholipase D activation by the M3 muscarinic receptor. *J Biol Chem* **278**: 33818-33830.

Mousavi SA, Malerod L, Berg T, and Kjekken R (2004) Clathrin-dependent endocytosis. *Biochem J* **377**: 1-16.

Rankovic M, Jacob L, Rankovic V, Brandenburg LO, Schröder H, Höllt V, and Koch T (2009) ADP-ribosylation factor 6 regulates mu-opioid receptor trafficking and signaling via activation of phospholipase D2. *Cell Signal* **21**: 1784-1793.

Robertson DN, Johnson MS, Moggach LO, Holland PJ, Lutz EM, and Mitchell R (2003) Selective interaction of ARF1 with the carboxy-terminal tail domain of the 5-HT_{2A} receptor. *Mol Pharmacol* **64**: 1239-1250.

Sandmann J, Peralta EG, and Wurtman RJ (1991) Coupling of transfected muscarinic acetylcholine receptor subtypes to phospholipase D. *J Biol Chem*, **266**, 6031-6034.

Sciorra, V.A. and Morris, A.J. (2002) Roles for lipid phosphate phosphatases in regulation of cellular signaling. *Biochim Biophys Acta* **1582**: 45-51.

Seachrist JL and Ferguson SS (2003) Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. *Life Sci* **100**: 225-235.

MOL 63107

Seifert A, Katschinski DM, Tonack S, Fischer B, and Navarette Santos A (2008) Significance of prolyl hydroxylase 2 in the interference of aryl hydrocarbon receptor and hypoxia-inducible factor-1 alpha signaling. *Chem Res Toxicol* **21**: 341-348.

Senogles SE (2000) The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine. *Mol Pharmacol* **58**: 455-462.

Shen Y, Xu L, and Foster DA (2001) Role for phospholipase D in receptor-mediated endocytosis. *Mol Cell Biol* **21**: 595-602.

Shinomura T, del Rio E, Breen KC, Downes CP, and McLaughlin M (2000) Activation of phospholipase D by metabotropic glutamate receptor agonists in rat cerebrocortical synaptosomes. *Br J Pharmacol* **131**: 1011-1018.

Snyder MD and Pierce SK (2006) A mutation in Epstein-Barr virus LMP"A reveals a role for phospholipase D in B-Cell antigen receptor trafficking. *Traffic* **7**: 993-1006.

Vergaraiaurequi S, San Miguel A, and Puertollano R (2006) Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. *Traffic* **7**: 686-698.

Zouwail S, Pettitt TR, Dove SK, Chibalina MV, Powner DJ, Haynes L, Wakelam MJ, and Insall RH (2005) Phospholipase D activity is essential for actin localization and actin-based motility in *Dictyostelium*. *Biochem J* **389**: 207-214.

MOL 63107

Footnotes:

¹ These authors contributed equally to this work.

* This work was supported by the Deutsche Forschungsgemeinschaft [Grant KR1740/10-1] and the Forschungszentrum “Center for Behavioural Brain Sciences” Land Sachsen-Anhalt.

MOL 63107

Legends for Figures:

Fig. 1. Role of PLD2-derived PA and DAG in the μ -opioid receptor endocytosis. A, Effect of PLD2-siRNA transfection on PLD2 expression in HEK293 cells. Cells stably expressing MOPr were transfected or not transfected with PLD2-siRNA as described under Materials and Methods. After 48 h, membrane proteins from MOPr-expressing cells transfected or not transfected with PLD2-siRNA were extracted and immunoblotted. PLD2 expression was monitored by western blot analysis using rabbit anti-human PLD2 antibody as previously described (Koch *et al.*, 2003; Koch *et al.*, 2001). Densitometric measurement revealed that 48 h after PLD2-siRNA transfection the PLD2 level was reduced to about 44% compared to untransfected control cells. Two additional experiments gave similar results. B, Effect of PPAP2A/B-siRNA transfection on PPAP2A and PPAP2B expression in HEK293 cells. Cells stably expressing MOPr were transfected or not transfected with PPAP2A/B-siRNA as described under Materials and Methods. After 48 h, RNA from MOPr-expressing cells transfected or not transfected with PPAP2A/B-siRNA was extracted and PPAP2A and PPAP2B expression level was quantified via real time RT-PCR as described under Materials and Methods. C, HEK293 cells stably expressing MOPr were transfected with PLD2-si RNA or treated with 0.5% 1-butanol for 30 min to block PLD2-expression or PLD2-mediated PA synthesis, respectively. Furthermore, PPAP2-mediated conversion of PA into DAG was blocked by transfection with PPAP2-siRNA or treatment with 250 μ M propranolol. The reconversion of DAG to PA was inhibited by application of the DGK-inhibitor R59949 (40 μ M). Cell surface receptors were determined by a quantitative enzyme immunoassay as described in Materials and Methods. Agonist-induced MOPr internalization was quantified as the percentage loss of surface receptors compared to the cells which were treated without agonist. Data presented are as means \pm S.E. from at least three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) between DAMGO-treated and untreated control cells (ANOVA followed by Bonferroni test).

Fig. 2. Role of PLD2-derived PA and DAG in the δ -opioid receptor endocytosis. A, Effect of PLD2-siRNA transfection on PLD2 expression in HEK293 cells. Cells stably expressing DOPr were transfected or not transfected with PLD2-siRNA as described under Materials and Methods. After 48 h, membrane proteins from DOPr-expressing cells transfected or not transfected with

MOL 63107

PLD2-siRNA were extracted and immunoblotted. PLD2 expression was monitored by western blot analysis using rabbit anti-human PLD antibody as previously described (Koch *et al.*, 2003; Koch *et al.*, 2001). Densitometric measurement revealed that 48 h after PLD2-siRNA transfection the PLD2 level was reduced to about 32% compared to untransfected control cells. Two additional experiments gave similar results. B, Effect of PPAP2A/B-siRNA transfection on PPAP2A and PPAP2B expression in HEK293 cells. Cells stably expressing DOPr were transfected or not transfected with PPAP2A/B-siRNA as described under Materials and Methods. After 48 h, RNA from DOPr-expressing cells transfected or not transfected with PPAP2A/B-siRNA was extracted and PPAP2A and PPAP2B expression level was quantified via real time RT-PCR as described under Materials and Methods. C, HEK293 cells stably expressing DOPr were transfected with PLD2-si RNA or treated with 0.5% 1-butanol for 30 min to block PLD2-expression or PLD2-mediated PA synthesis, respectively. Furthermore, PPAP2-mediated conversion of PA into DAG was blocked by transfection with PPAP2-siRNA or treatment with 250 μ M propranolol. The reconversion of DAG to PA was inhibited by application of the DGK-inhibitor R59949 (40 μ M). Cell surface receptors were determined by a quantitative enzyme immunoassay as described in Materials and Methods. Agonist-induced DOPr internalization was quantified as the percentage loss of surface receptors compared to the cells which were treated without agonist. Data presented are as means \pm S.E. from at least three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) between DPDPE-treated and untreated control cells (ANOVA followed by Bonferroni test).

Fig. 3. The DAG analog, DOG, enhances agonist-induced opioid receptor endocytosis in a PKC-independent manner and bypasses the PLD2-siRNA- or PPAP2-siRNA-mediated impairment of opioid-receptor endocytosis. A, Quantitative analysis of MOPr internalization in MOPr expressing HEK293 cells, which were stimulated with or without 1 μ M DAMGO for 30 min in the presence or absence of 150 μ M DOG. Note that the stimulatory effect of DOG on the receptor endocytosis was neither influenced by treatment with PKC inhibitors (5 μ M chelerythrine chloride (Che) or 1 μ M calphostin C (Calph)) nor by transfection of MOPr expressing cells with PLD2-siRNA or PPAP2-siRNA. B, Quantitative analysis of DOPr internalization in DOPr expressing HEK293 cells, which were stimulated with or without 0.1 μ M DPDPE for 30 min in the presence or absence of 150 μ M DOG. Note that the stimulatory effect of DOG on the receptor endocytosis was neither influenced by treatment with PKC inhibitors (5 μ M

MOL 63107

chelerythrine chloride (Che) or 1 μ M calphostin C (Calph)) nor by transfection of DOPr expressing cells with PLD2-siRNA or PPAP2-siRNA. For quantitative analysis of receptor internalization in A and B, agonist-induced opioid receptor internalization was measured and calculated as described in Materials and Methods. Data are presented as means \pm S.E. from three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) compared to the treatment with agonist alone (ANOVA followed by Bonferroni test).

Fig. 4. PLD2 is involved in the activation of p38 MAPK, which is required for agonist-induced opioid receptor endocytosis. A, Blocking of opioid receptor-mediated p38 MAPK activation by the PLD inhibitor 1-butanol. As indicated, MOPr- or DOPr-expressing HEK293 cells were stimulated with agonist in the presence or absence of 0.5% 1-butanol or isobutanol for 5 min. Subsequently cells were lysed and subjected to Western blot to analyze phosphorylated p38 MAPK kinase as described in Materials and Methods. B, Agonist-induced opioid receptor endocytosis was attenuated by inhibition of p38 MAPK. HEK293 cells expressing MOPr or DOPr were treated with agonist for 30 min in the presence or absence of 10 μ M p38 MAPK inhibitor SB203580. Cell surface opioid receptors were determined by quantitative enzyme immunoassay as described in Material and Methods. Data are presented as means \pm S.E. from three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) between SB203580 treated cells and untreated controls (ANOVA followed by Bonferroni test).

Fig. 5. MOPr-mediated activation of p38 MAPK can be blocked by inhibition of PLD2 and is PKC-independent. A, Effect of agonist-induced MOPr activation on the p38 MAPK activity in the presence or absence of DOG, propranolol or chelerythrine. Cell were treated with or without 150 μ M DOG, 5 μ M chelerythrine, or 250 μ M propranolol as indicated. As a marker for p38 MAPK activation we determined the level of phosphorylated p38 MAPK by western blot analysis as described under Materials and Methods. B, Effect of transfection of MOPr expressing cells with PLD2-siRNA or PPAP2-siRNA on the DAMGO-induced p38 MAPK activation. C, The stimulatory effect of DOG on the p38 MAPK activation in MOPr expressing cells was not influenced by the transfection with PLD2-siRNA or PPAP2-siRNA. Quantitative data from Fig. 5 are presented as means \pm S.E. from three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) compared to untreated control cells (ANOVA followed by Bonferroni test).

MOL 63107

Fig. 6. DOPr-mediated activation of p38 MAPK can be blocked by inhibition of PLD2 and is PKC-independent. A, Effect of agonist-induced DOPr activation on the p38 MAPK activity in the presence or absence of DOG, propranolol or chelerythrine. Cells were treated with or without 150 μ M DOG, 5 μ M chelerythrine, or 250 μ M propranolol as indicated. As a marker for p38 MAPK activation we determined the level of phosphorylated p38 MAPK by western blot analysis as described under Materials and Methods. B, Effect of transfection of DOPr expressing cells with PLD2-siRNA or PPAP2-siRNA on the DPDPE-induced p38 MAPK activation. C, The stimulatory effect of DOG on the p38 MAPK activation in DOPr expressing cells was not influenced by the transfection with PLD2-siRNA or PPAP2-siRNA. Quantitative data from Fig. 6 are presented as means \pm S.E. from three independent experiments performed in triplicate. *Significant difference ($p < 0.05$) compared to untreated control cells (ANOVA followed by Bonferroni test).

Fig. 7. Effect of PLD2-siRNA or PPAP2-siRNA transfection on the DAMGO- or DPDPE-induced p38 MAPK activation in neuronal SHSY-5Y cells. SHSY-5Y cells endogenously expressing MOPr and DOPr were transfected or not transfected with PLD2-siRNA or PPAP2-siRNA as described under Materials and Methods. 48 h after transfection, membrane proteins from SHSY-5Y cells were extracted and immunoblotted. As a marker for p38 MAPK activation we determined the level of phosphorylated p38 MAPK by western blot analysis as described under Materials and Methods. Representative immunoblots from one of three independent experiments are shown. Quantitative data from Fig. 7 are expressed as the fold p38 MAPK phosphorylation over basal in untreated cells and are presented as means \pm S.E. from three independent experiments. *Significant difference ($p < 0.05$) and **significant difference ($p < 0.01$) compared to untreated control cells (ANOVA followed by Bonferroni test).

Fig. 8. Effect of PLD2-siRNA or PPAP2-siRNA transfection on the DAMGO- or DPDPE-induced EEA1 phosphorylation in neuronal SHSY-5Y cells. SHSY-5Y cells endogenously expressing MOPr and DOPr were transfected or not transfected with PLD2-siRNA or PPAP2-siRNA as described under Materials and Methods. 48 h after transfection, proteins from SHSY-5Y cells were extracted and endogenous EEA1 protein was immunoprecipitated and blotted with antibodies against EEA1 or phospho-Thr. As a marker for EEA1 activation we determined the

MOL 63107

level of phosphorylated EEA1 by western blot analysis as described under Materials and Methods. Representative immunoblots from one of three independent experiments are shown. Quantitative data from Fig. 8 are expressed as the fold EEA1 phosphorylation over basal in untreated cells and are presented as means \pm S.E. from three independent experiments. *Significant difference ($p < 0.05$) compared to untreated control cells (ANOVA followed by Bonferroni test).

Figure 1






Figure 2







Figure 3

A



B





Figure 4

A



B




Figure 5








Figure 6

A



B



C




Figure 7




Figure 8

